A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma

被引：0
|
作者：
Tillmanns, T. D.
Lowe, M. P.
Schwartzberg, L. S.
Walker, M. S.
Stepanski, E. J.
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] West Clin, Memphis, TN USA
[3] ACORN Res, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5009
引用
收藏
页数：1
相关论文
共 50 条
  • [21] EFFECTIVENESS OF BEVACIZUMAB IN PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER
    Pinto, R.
    Monteiro, S.
    Lima, B.
    Lopes, A. R.
    Abreu, M.
    Ferreira, M.
    Sousa, S.
    Redondo, P.
    Pereira, D.
    Savva-Bordalo, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A271 - A271
  • [22] Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
    Osman, Mohammed A.
    Elkady, Mohammad S.
    Nasr, Khalid E.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 35 - 41
  • [23] Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
    Swensen, Ron E.
    Goff, Barbara Ann
    Childs, Jennifer
    Higgins, Doreen
    Gooley, Theodore
    Fintak, Patricia A.
    Buening, Barbara
    Disis, Mary L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
    Zhao, Ling-Qin
    Gao, Wen
    Zhang, Ping
    Zhang, Ying-Li
    Fang, Chen-Yan
    Shou, Hua-Feng
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (12) : 3739 - 3753
  • [25] Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
    Ling-Qin Zhao
    Wen Gao
    Ping Zhang
    Ying-Li Zhang
    Chen-Yan Fang
    Hua-Feng Shou
    World Journal of Clinical Cases, 2022, 10 (12) : 3739 - 3753
  • [26] PHASE II TRIAL EVALUATING EFFICACY AND SAFETY OF STANDARD OF CARE WITH OR WITHOUT BEVACIZUMAB IN PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
    Nishikawa, N.
    Shoji, T.
    Enomoto, T.
    Abe, M.
    Okamoto, A.
    Saito, T.
    Oishi, T.
    Nagase, S.
    Mori, M.
    Inokuchi, Y.
    Kamiura, S. K.
    Sugiyama, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A10 - A11
  • [27] Phase II study of gemcitabine and vinorebline in patients with persistent or recurrent platinum-resistant ovarian or primary peritoneal cancer: A study of the Korean Cancer Study Group.
    Hong, Sook Hee
    Byun, Jae Ho
    Lee, Soohyeon
    Kim, Hoon-Gu
    Lee, Hyo Jin
    Jung, Kyung Hae
    Lee, Sang-Cheol
    Lee, Na-Ri
    Yun, Jina
    Hong, Dae-Sik
    Woo, In Sook
    Park, Kyong Hwa
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator's choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.
    Olawaiye, Alexander
    Monk, Bradley J.
    Herzog, Thomas J.
    Copeland, Larry J.
    Coleman, Robert L.
    Moore, Kathleen N.
    Randall, Leslie M.
    Slomovitz, Brian M.
    O'Malley, David M.
    Eskander, Ramez Nassef
    Pothuri, Bhavana
    Van Gorp, Toon
    Pignata, Sandro
    Nicum, Shibani
    Tudor, Iulia Cristina
    Nguyen, Dorothy D.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Berkenblit, A
    Seiden, MV
    Matulonis, UA
    Penson, RT
    Krasner, CN
    Roche, M
    Mezzetti, L
    Atkinson, T
    Cannistra, SA
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 624 - 631
  • [30] A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Moore, K. N.
    Cadoo, K. A.
    Chambers, S.
    Ghamande, S.
    Konecny, G.
    Oza, A. M.
    Chen, L-M.
    Konstantinopoulos, P. A.
    Lea, J.
    Spitz, D.
    Uyar, D.
    Mugundu, G.
    Laing, N.
    Strickland, D. K.
    Jones, S.
    Burris, H.
    Spigel, D. R.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2017, 28
12345